Drug intelligence / Profile preview

FB-4001

Development stage: Preclinical
Lead developer: FNCT Biotech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FB-4001 is a preclinical-stage bispecific antibody (BsAb) being developed by FNCT Biotech for the treatment of solid tumors. As of 2024, the specific molecular targets of the antibody have not been disclosed by the sponsor. The asset is part of FNCT Biotech's oncology pipeline, which utilizes multi-specific antibody platforms to enhance therapeutic efficacy and overcome resistance in cancer treatment. It is currently in the discovery or candidate selection phase of development.

Other names: FB-4001FB4001FB 4001

Beyond the preview

Go deeper on FB-4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FB-4001.

Explore the full profile